Outset Medical to Announce Fourth Quarter and Full-Year Results
Outset Medical, Inc. (NASDAQ: OM), a pioneering force in medical technology, is gearing up to present its financial performance results for the fourth quarter and the entire year of 2024. The announcement is set to occur following the market closure on a Wednesday in February.
Conference Call to Discuss Financial Performance
On the same date, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Outset Medical's leadership team, including Leslie Trigg, Chair and Chief Executive Officer, alongside Nabeel Ahmed, Chief Financial Officer, will host a conference call. This call is a valuable opportunity for stakeholders to gain in-depth insights into the company's financial and operational results.
Joining the Conference Call
Individuals interested in joining the discussion can easily register online. After the registration process, participants will receive unique dial-in numbers and a PIN to access the call. It's recommended to complete registration more than 15 minutes prior to the call's start for seamless access.
Transforming Dialysis with Innovative Technology
Outset Medical is revolutionizing the dialysis experience for both patients and healthcare providers. By introducing groundbreaking technology, the company aims to significantly lower the costs and complexities traditionally associated with dialysis. Their flagship product, the Tablo® Hemodialysis System, has recently been FDA cleared, enabling its use across various healthcare settings, from hospitals to home care.
Tablo: A Game Changer in Dialysis
Tablo stands out as a comprehensive solution, facilitating dialysis treatments at any location and by any personnel. This advanced system integrates water purification with on-demand dialysate production, effectively creating a mobile dialysis clinic. With its two-way wireless data transmission and an innovative data analytics platform, Tablo is reshaping how dialysis care is delivered.
The Future of Dialysis Care
Outset Medical's commitment to enhancing dialysis technology continues to push boundaries, aiming for improved patient care and operational efficiency in healthcare facilities. The integration of new technologies signifies a transformative period in dialysis treatment that can make a significant difference in patients' lives.
Contact and Investor Relations
Individuals looking for more information or wishing to discuss investor relations can connect with Jim Mazzola. As part of the Investor Relations team, he is ready to assist through direct communication via email.
Frequently Asked Questions
What is the purpose of the upcoming financial results announcement?
The announcement aims to communicate Outset Medical's financial performance for the fourth quarter and the entire year of 2024 to stakeholders and investors.
Who will lead the conference call?
The conference call will be led by Leslie Trigg, the Chair and CEO, along with CFO Nabeel Ahmed, providing insights into financial and operational results.
How can I join the conference call?
To join the call, interested individuals need to register online, after which they will receive unique dial-in details to access the session.
What is the Tablo Hemodialysis System?
The Tablo Hemodialysis System is an FDA-cleared technology that simplifies the dialysis process and can be used in various healthcare settings, including homes.
How does Outset Medical ensure quality in dialysis care?
Outset Medical intertwines cutting-edge technology with operational strategies, enhancing patient care and allowing for flexible, efficient treatment options.
